newsfilter
← Latest News
Business Wire·

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Partnership with Everest Medicines will address a critical unmet medical need for patients with active lupus nephritis in Asia Kezar is eligible to receive up to $132.5 million in total payments, as well as tiered